ARA-290 (16mg)

Research Overview

An 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin. It selectively binds the heterodimeric innate repair receptor (EPOR/βcR) expressed on injured tissue—triggering the cytoprotective and anti-inflammatory arm of EPO signaling without stimulating hematopoiesis via the classic EPOR homodimer.

Origin: Synthetic peptide derived from the aqueous face of helix B of erythropoietin (EPO); engineered to retain tissue-protective activity without hematopoiesis

Mechanism of Action

• Innate repair receptor (EPOR/βcR) agonism

• JAK2-STAT signaling in injured tissue

• Reduction of pro-inflammatory cytokines (TNF-α, IL-6)

• Endothelial protection against ischemic injury

• Promotion of peripheral nerve regeneration

Primary Research Areas

• Sarcoidosis-associated small-fiber neuropathy

• Diabetic peripheral neuropathy

• Ischemic injury and reperfusion

• Chronic inflammation research

Key Published Findings

• Improved corneal nerve fibre density and pain scores in sarcoid small-fiber neuropathy (Brines et al., Mol Med 2014)

• Reduced neuropathic pain in phase-2 diabetic neuropathy trial (Dahan et al., 2013)

• Tissue-protective activity without altering haematocrit in rodent and primate models

Research Protocol

Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.

Storage

-20°C lyophilized

Important Notice

ARA-290 (16mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.